{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T20:01:10Z","timestamp":1695499270142},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,6,23]],"date-time":"2013-06-23T00:00:00Z","timestamp":1371945600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathologe"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1007\/s00292-013-1763-4","type":"journal-article","created":{"date-parts":[[2013,6,21]],"date-time":"2013-06-21T08:24:34Z","timestamp":1371803074000},"page":"293-304","source":"Crossref","is-referenced-by-count":5,"title":["Mammakarzinom: aktuelle Empfehlungen f\u00fcr Pathologen auf Basis der S3-Leitlinie"],"prefix":"10.1007","volume":"34","author":[{"given":"A.","family":"Lebeau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Kreipe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Dietel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Schlake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Kreienberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,6,23]]},"reference":[{"key":"1763_CR1","doi-asserted-by":"crossref","unstructured":"Kreienberg R, Albert US, Follmann M et al (2012) Interdisziplin\u00e4re S3-Leitlinie f\u00fcr die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. In: Kreienberg R (Hrsg) Leitlinienprogramm Onkologie. 3.\u00a0Aufl. W. Zuckschwerdt, M\u00fcnchen","DOI":"10.1055\/s-0033-1355476"},{"key":"1763_CR2","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1200\/JCO.2008.17.5182","volume":"27","author":"Dunne","year":"2009","unstructured":"Dunne C, Burke JP, Morrow M et al (2009) Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol 27:1615\u20131620","journal-title":"J Clin Oncol"},{"key":"1763_CR3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/jnci\/djs142","volume":"104","author":"Wang","year":"2012","unstructured":"Wang SY, Chu H, Shamliyan T et al (2012) Network meta-analysis of margin threshold for women with ductal carcinoma in situ. J Natl Cancer Inst 104:507\u2013516","journal-title":"J Natl Cancer Inst"},{"key":"1763_CR4","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1016\/j.ejca.2010.07.043","volume":"46","author":"Houssami","year":"2010","unstructured":"Houssami N, Macaskill P, Marinovich ML et al (2010) Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy. Eur J Cancer 46:3219\u20133232","journal-title":"Eur J Cancer"},{"key":"1763_CR5","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1002\/1097-0142(19940915)74:6<1746::AID-CNCR2820740617>3.0.CO;2-Y","volume":"74","author":"Schnitt","year":"1994","unstructured":"Schnitt SJ, Abner A, Gelman R et al (1994) The relationship between microscopic margins of resection and the risk of local recurrence in patients with breast cancer treated with breast-conserving surgery and radiation therapy. Cancer 74:1746\u20131751.","journal-title":"Cancer"},{"key":"1763_CR6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-0029-1213757","volume":"134","author":"Wittekind","year":"2009","unstructured":"Wittekind C (2009) Anwendung der Residualtumorklassifikation: Residualtumorklassifikation in der Onkologie \u2013 Anwendungen und Probleme. Zentralbl Chir 134:3\u20136","journal-title":"Zentralbl Chir"},{"key":"1763_CR7","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/SLA.0b013e3181f08f32","volume":"252","author":"Giuliano","year":"2010","unstructured":"Giuliano AE, McCall L, Beitsch P et al (2010) Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 252:426\u2013432","journal-title":"Ann Surg"},{"key":"1763_CR8","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","volume":"22","author":"Goldhirsch","year":"2011","unstructured":"Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes\u2013dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22:1736\u20131747","journal-title":"Ann Oncol"},{"key":"1763_CR9","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/jnci\/djr393","volume":"103","author":"Dowsett","year":"2011","unstructured":"Dowsett M, Nielsen TO, A\u2019hern R et al (2011) Assessment of Ki67 in breast cancer: recommendations from the international ki67 in breast cancer working group. J Natl Cancer Inst 103:1656\u20131664","journal-title":"J Natl Cancer Inst"},{"key":"1763_CR10","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/sj.bjc.6603756","volume":"96","author":"Azambuja","year":"2007","unstructured":"Azambuja E de, Cardoso F, Castro G de Jr et al (2007) Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 96:1504\u20131513","journal-title":"Br J Cancer"},{"key":"1763_CR11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.breast.2008.02.002","volume":"17","author":"Stuart-Harris","year":"2008","unstructured":"Stuart-Harris R, Caldas C, Pinder SE, Pharoah P (2008) Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 17:323\u2013334","journal-title":"Breast"},{"key":"1763_CR12","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1470-2045(09)70262-1","volume":"11","author":"Yerushalmi","year":"2010","unstructured":"Yerushalmi R, Woods R, Ravdin PM et al (2010) Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11:174\u2013183","journal-title":"Lancet Oncol"},{"key":"1763_CR13","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1365-2559.2010.03620.x","volume":"57","author":"Kwok","year":"2010","unstructured":"Kwok TC, Rakha EA, Lee AH et al (2010) Histological grading of breast cancer on needle core biopsy: the role of immunohistochemical assessment of proliferation. Histopathology 57:212\u2013219","journal-title":"Histopathology"},{"key":"1763_CR14","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/GIM.0b013e3181928f56","volume":"11","author":"EGAPP","year":"2009","unstructured":"EGAPP Working Group (2009) Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer? Genet Med 11:66\u201373.","journal-title":"Genet Med"},{"key":"1763_CR15","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1186\/1471-2407-12-456","volume":"12","author":"Kronenwett","year":"2012","unstructured":"Kronenwett R, Bohmann K, Prinzler J et al (2012) Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test. BMC Cancer 12:456. doi:10.1186\/1471-2407-12-456","journal-title":"BMC Cancer"},{"key":"1763_CR16","unstructured":"UICC (2010) TNM classification of malignant tumours. In: Sobin L, Gospodarowicz M, Wittekind C (Hrsg) 7.\u00a0Aufl. Wiley-Liss, New York"},{"key":"1763_CR17","unstructured":"WHO (2003) World Health Organization classification of tumours. Pathology and genetics of tumours of the breast and female genital organs. In: Tavassoli FA, Devilee P (Hrsg) IARC Press, Lyon:9\u2013112"},{"key":"1763_CR18","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","volume":"19","author":"Elston","year":"1991","unstructured":"Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403\u2013410","journal-title":"Histopathology"},{"key":"1763_CR19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10549-010-1228-x","volume":"125","author":"Minckwitz","year":"2011","unstructured":"Minckwitz G von, Untch M, Nuesch E et al (2011) Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 125:145\u2013156","journal-title":"Breast Cancer Res Treat"},{"key":"1763_CR20","unstructured":"ASCO clinical notice. HER2 clinical notice. http:\/\/www.asco.org\/ASCO\/Downloads\/Cancer%20Policy%20and%20Clinical%20Affairs\/Clinical%20Affairs%20(derivative%20products)\/HER%202\/HER%202%20Clinical%20Notice%201.13.11.pdf. Zugegriffen: 30. Dez. 2012"},{"key":"1763_CR21","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.1999.17.5.1474","volume":"17","author":"Harvey","year":"1999","unstructured":"Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474\u20131481","journal-title":"J Clin Oncol"},{"key":"1763_CR22","first-page":"138","volume":"8","author":"Remmele","year":"1987","unstructured":"Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8:138\u2013140","journal-title":"Pathologe"},{"key":"1763_CR23","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","volume":"28","author":"Hammond","year":"2010","unstructured":"Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784\u20132795","journal-title":"J Clin Oncol"},{"key":"1763_CR24","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","volume":"25","author":"Wolff","year":"2007","unstructured":"Wolff AC, Hammond ME, Schwartz JN et al (2007a) American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118\u2013145","journal-title":"J Clin Oncol"},{"key":"1763_CR25","doi-asserted-by":"crossref","first-page":"e458","DOI":"10.1200\/JCO.2011.35.2245","volume":"29","author":"Hammond","year":"2011","unstructured":"Hammond ME, Hayes DF, Wolff AC (2011) Clinical Notice for American Society of Clinical Oncology- College of American Pathologists guideline recommendations on ER\/PgR and HER2 testing in breast cancer. J Clin Oncol 29:e458","journal-title":"J Clin Oncol"},{"key":"1763_CR26","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1200\/JCO.2007.11.4363","volume":"Oncol","author":"Wolff","year":"2007","unstructured":"Wolff AC, Hammond ME, Schwartz JN, Hayes DF (2007b) In Reply. J Clin Oncol (25):4021\u20134023","journal-title":"J Clin"},{"key":"1763_CR27","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1200\/JCO.2007.14.8197","volume":"27","author":"Sauter","year":"2009","unstructured":"Sauter G, Lee J, Bartlett JM et al (2009) Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 27:1323\u20131333","journal-title":"J Clin Oncol"},{"key":"1763_CR28","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ejso.2011.01.009","volume":"37","author":"Hussain","year":"2011","unstructured":"Hussain M, Cunnick GH (2011) Management of lobular carcinoma in-situ and atypical lobular hyperplasia of the breast\u2013a review. Eur J Surg Oncol 37:279\u2013289","journal-title":"Eur J Surg Oncol"},{"key":"1763_CR29","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1038\/modpathol.2010.35","volume":"23","author":"O","year":"2010","unstructured":"O\u2019Malley FP (2010) Lobular neoplasia: morphology, biological potential and management in core biopsies. Mod Pathol 23(Suppl 2):S14-S25","journal-title":"Mod Pathol"}],"container-title":["Der Pathologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-013-1763-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00292-013-1763-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-013-1763-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T00:27:38Z","timestamp":1645835258000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00292-013-1763-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,23]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["1763"],"URL":"https:\/\/doi.org\/10.1007\/s00292-013-1763-4","relation":{},"ISSN":["0172-8113","1432-1963"],"issn-type":[{"value":"0172-8113","type":"print"},{"value":"1432-1963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,23]]}}}